<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599480</url>
  </required_header>
  <id_info>
    <org_study_id>Beta3_LVH V1.0</org_study_id>
    <nct_id>NCT02599480</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure</brief_title>
  <acronym>Beta3_LVH</acronym>
  <official_title>A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean-Luc Balligand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zentrum für Klinische Studien Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Clinical Research Infrastructure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Lisbon Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cardiovascular Research Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papa Giovanni XXIII Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the
      prevention of heart failure. This is a two armed, prospective, randomized,
      placebo-controlled, multi-centric european phase IIb trial with placebo and mirabegron
      distributed in a 1:1 fashion. The patients enrolled will have cardiac structural remodeling
      with or without symptoms of heart failure (maximum NYHA II).

      Patients will be monitored for change in left ventricular mass (assessed by cardiac MRI)
      and/or changes in diastolic function (assessed by echocardiography) after 12 months of
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Heart failure (HF) represents a major and growing public health burden. Patients
      with HF are classically divided into two groups: those with HF with preserved ejection
      fraction (HFpEF), and those with HF and reduced ejection fraction (HFrEF). As HF is a
      progressive disorder increasing with age, the proportion of these patients is rising due to
      the aging of the population. Beside costs, HFpEF also puts a heavy burden on the quality of
      life of (mostly elderly) patients, with a loss of autonomy and the dyscomfort of repeated
      hospitalisations. Therefore, HFpEF is a chronic, costly, debilitating disease.

      A major contributor to HFpEF is myocardial remodelling, e.g. hypertrophy and fibrosis, as
      well as cellular functional/structural modifications leading to alteration in contractile
      properties and ventricular distensibility. Unfortunately, there are currently no
      evidence-based treatment strategies.

      Study claim The proposed clinical trial will provide a proof of concept in humans for the
      clinical efficacy of a novel therapeutic concept: β3AR activation to attenuate/prevent
      cardiac remodeling. Recently, a new, specific agonist at human β3-AR (mirabegron) with higher
      benefit/risk balance was developed and marketed for clinical use in a non-cardiovascular
      disease (overactive bladder disease). The trial will test the drug repurposing of mirabegron
      for the prevention of cardiac remodeling leading to HFpEF.

      Using pre-clinical models, the investigators demonstrated that activation of β3AR attenuates
      myocardial hypertrophy and fibrosis in response to neurohormonal or hemodynamic stresses,
      without compromising LV function. Therefore, the recent availability of this new drug offers
      the possibility to test the potential benefit of mirabegron (vs placebo) as add-on therapy
      (on top of standard care) to prevent/delay myocardial remodelling in patients at high risk of
      developing HFpEF.

      Who can participate? Patients with structural cardiac disease with or without HF symptoms
      (max. NYHA 2).

      What does the study involve? Patients will be requested to go 5 times to the hospital to
      perform cardiac MRI (3X), echocardiography (3X), exercise tolerance test (2X), Pet scanning
      (2X) and blood sampling (4X).

      Who is the sponsor? The Université catholique de Louvain (UCL) is the academic sponsor and
      Prof. Jean-Luc Balligand is the principal coordinator of the study.

      Who is funding the study? Beta3_LVH is an investigator-initiated project funded by a Horizon
      2020 grant from the European Commission.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular mass index (LVMI)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in left ventricular mass index (LVMI in g/m2, defined as left ventricular mass divided by body surface) measured at baseline and 12 months after randomisation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in diastolic function</measure>
    <time_frame>12 months</time_frame>
    <description>Change in diastolic function, assessed as the ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity (E/e') measured at baseline and 12 months after randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac fibrosis at baseline and at 12 months. Fibrosis is a key pathogenic mechanism of diastolic dysfunction, which is at the origin of HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume index</measure>
    <time_frame>12 months</time_frame>
    <description>Left atrial volume index at baseline and at 12 months. This parameter determines diastolic filling (and was shown to predict treatment efficacy in HFpEF in the J-DHF trial (Yamamoto et al. 2013))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV mass index (by cardiac MRI)</measure>
    <time_frame>6 months</time_frame>
    <description>LV mass index (by cardiac MRI) at 6 months,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function (E/e')</measure>
    <time_frame>6 months</time_frame>
    <description>Diastolic function (E/e') at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum biomarkers</measure>
    <time_frame>3, 6, 12 months</time_frame>
    <description>serum biomarkers (Galectin3, GDF15, NT-proBNP, hsTnT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters</measure>
    <time_frame>3, 6, 12 months</time_frame>
    <description>metabolic parameters (fasting glucose, modified HOMA test, HbA1c, serum lipids)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal exercise capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Maximal exercise capacity (peak VO2) at baseline and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">297</enrollment>
  <condition>Hypertrophy, Left Ventricular</condition>
  <arm_group>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be orally administererd with a placebo once a day during 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>50 mg daily during 12 months</description>
    <arm_group_label>mirabegron</arm_group_label>
    <other_name>Betmiga, Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Echocardiography</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Maximal exercise capacity</intervention_name>
    <description>Maximal exercise capacity</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling for study assessments and future exploratory studies.</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endothelial function measurement</intervention_name>
    <description>EndoPAT assessment</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18FDG-PET</intervention_name>
    <description>PET scanning for beige/brown fat activation</description>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 90 years

          -  Arterial hypertension on stable therapy according to current guideline algorithms
             (including stable medication for at least four weeks before inclusion),

          -  Morphological signs of structural cardiac remodelling by echocardiography, i.e.
             increased LV mass index (110 g/m2 or higher for female; 134 g/m2 or higher for male
             subjects (Devereux, Reichek 1977)) or end-diastolic wall thickness &gt;13 mm in at least
             one wall segment

          -  Patients may have atrial fibrillation (AF), but with well-regulated ventricular
             response, i.e. heart rate&lt;100/min (RACE II - (Groenveld et al. 2013, 2013)),

          -  Written informed consent

          -  For subjects unable to read and/or write, oral informed consent observed by an
             independent witness is acceptable if the subject has fully understood oral information
             given by the Investigator. The witness should sign the consent form on behalf of the
             subject.

        Exclusion Criteria:

          -  Unstable hypertension with systolic BP≥160 mm Hg and/or diastolic BP≥100 mm Hg (based
             on office measurement, not ambulatory measurement)

          -  Documented ischemic cardiac disease

          -  History of hospitalization for overt heart failure within last 12 months

          -  Patients after heart transplantation

          -  Genetic hypertrophic or dilated cardiomyopathy

          -  Dysthyroidism.

          -  Severe valvulopathy

          -  NYHA-class &gt; II

          -  BMI &gt;40 kg/m2

          -  EF &lt; 50%, regardless of symptoms

          -  Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive
             pressure (CPAP) treatment for sleep apnea syndrome may be included, provided they have
             been under regular treatment for at least one year before inclusion in the study

          -  eGFR &lt; 30 ml/min (by MDRD formula)

          -  Abnormal liver function tests

          -  Type I diabetes, complicated type II diabetes

          -  Patients with anemia

          -  Patients with bladder outlet obstruction

          -  Patients using antimuscarinic cholinergic drugs for treatment of OAB

          -  Current use of digitalis, bupranolol, propranolol, nebivolol

          -  Patients continuously treated with Sildenafil or other PDE5 inhibitors.

          -  Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole,
             posaconazole, voriconazole)

          -  Current treatment with mirabegron or indication for future treatment with mirabegron
             due to other indications

          -  Contraindication for MRI

          -  Pregnant or nursing women

          -  Participation in any other interventional trial

          -  Fertile women (within two years of their last menstruation) without appropriate
             contraceptive measures (hormonal implant, injections, oral contraceptives,
             intrauterine devices, partner with vasectomy) while participating in the trial
             (participants using a hormone-based method have to be informed of possible effects
             from the trial medication on contraception)

          -  Contraindication to mirabegron (e.g. hypersensitivity) or any other components of the
             trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes university hospital (CHU Nantes)</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cardiovascular Research Berlin (CCR/Charité)</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Göttingen (UMG-GOE)</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens University Medical School (NKUA)</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Papa Giovanni XXIII&quot; (HPG23)</name>
      <address>
        <city>Bergamo</city>
        <zip>1 - 24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Heart Diseases at Wroclaw Medical University (UMW)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Association for Research and Development of the Faculty of Medicine (AIDFM)</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford - Division of Cardiovascular Medicine (UOXF)</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Götz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014 Jan 28;129(4):451-62. doi: 10.1161/CIRCULATIONAHA.113.004940. Epub 2013 Nov 4.</citation>
    <PMID>24190960</PMID>
  </reference>
  <reference>
    <citation>Balligand JL. beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade &quot;Stop or Encore?&quot;. J Am Coll Cardiol. 2009 Apr 28;53(17):1539-42. doi: 10.1016/j.jacc.2009.01.048.</citation>
    <PMID>19389565</PMID>
  </reference>
  <reference>
    <citation>Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135-63. doi: 10.1016/S1054-3589(10)59005-7. Review.</citation>
    <PMID>20933201</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Jean-Luc Balligand</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>cardiac remodeling,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

